<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111115">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02119065</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-13176</org_study_id>
    <secondary_id>NCI-2014-00278</secondary_id>
    <nct_id>NCT02119065</nct_id>
  </id_info>
  <brief_title>Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT</brief_title>
  <official_title>PET/CT-Derived Hepatopulmonary Shunt Fraction Following Yttrium-90 Radioembolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies positron emission tomography (PET)/computed tomography
      (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or
      cancer that has spread to the liver (metastatic) that can not be removed by surgery. Imaging
      procedures, such as PET/CT after Yttrium-90 bead therapy, may help see if the beads are
      present in the lung and compare the results with the pre-therapy imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the absolute difference in post-therapy Yttrium-90 microsphere
      hepatopulmonary shunt fraction and the pre-therapy Technetium-99m macroaggregated albumin
      hepatopulmonary shunt fraction in patients with unresectable primary hepatic malignancy and
      hepatic metastatic disease.

      SECONDARY OBJECTIVES:

      I. To quantify and compare the pre-therapy Technetium-99m macroaggregated albumin particle
      sizes and post-therapy Yttrium-90 microsphere sizes.

      OUTLINE:

      Patients receive routine pre-therapy Technetium-99m macroaggregated albumin. Patients then
      undergo routine radioembolization with Yttrium-90 microspheres. Within 36 hours after
      radioembolization, patients undergo PET/CT imaging.

      Available imaging, clinical, interventional and surgical follow-up data for 2 years after
      completion of enrollment in the study will be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values</measure>
    <time_frame>Baseline to up to 36 hours after radioembolization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-parametric Wilcoxon signed rank testing will be used to compare the 99mTc MAA and 90Y microsphere shunt fractions. Alternatively, a natural log transformation of the hepatopulmonary shunt fractions may be used to normalize these data for subsequent parametric paired t-test analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Descriptive statistical assessment of Technetium-99m macroaggregated albumin particle size and microsphere size for each patient (e.g., mean, median, standard deviation, distribution, etc.) will be performed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Adult Primary Liver Cancer</condition>
  <condition>Liver Metastases</condition>
  <condition>Localized Unresectable Adult Primary Liver Cancer</condition>
  <condition>Recurrent Adult Primary Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Health Services Research (PET/CT scan)</arm_group_label>
    <description>Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Health Services Research (PET/CT scan)</arm_group_label>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, positron emission</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Health Services Research (PET/CT scan)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population includes patients with unresectable liver metastases or malignancy
        who are referred to The Ohio State University Wexner Medical Center for Yttrium-90
        microsphere radioembolization therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who undergo intra-arterial hepatic 99mTc MAA evaluation in anticipation of
             90Y microsphere radioembolization

        Exclusion Criteria:

          -  Patients who are unable to give consent

          -  Prisoners
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadwick Wright</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State University Comprehensive Cancer Cancer</last_name>
    <phone>1-800-293-5066</phone>
    <email>Jamesline@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadwick L. Wright</last_name>
      <phone>614-293-8315</phone>
      <email>Chadwick.Wright@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bonnie Willams</last_name>
      <phone>614-293-6237</phone>
      <email>bonnie.williams@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chadwick L. Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Chadwick Wright</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Yttrium-90 Radioembolization</keyword>
  <keyword>hepatic malignancy</keyword>
  <keyword>hepatic metastatic disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
